Grifols SA banner

Intrinsic Value

The intrinsic value of Grifols SA (GRF.P) under the Base Case is 10 EUR per share. Compared with the current market price of 7.86 EUR, the stock appears Undervalued by 21% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

GRF.P Intrinsic Value
€10
Undervaluation 21%
Intrinsic Value
Price €7.86
Alert me when GRF.P is below its intrinsic value
Today €7.00 · 10.9% below the current price

GRF.P is valued in line with its history. A discount of this size has been typical over the past 5 years.

Alternatives to GRF.P

Fundamental Analysis

What Grifols Does

Biotechnology Health Care

Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.

Headquarters
Spain ES
Employees
25 000
IPO date
May 17, 2006
Read the full company overview
View Company Overview

Grifols has no economic moat

No Moat Narrow Wide

Grifols SA lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Earnings Waterfall
Grifols SA

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one GRF.P stock?

The intrinsic value for Grifols SA (GRF.P) under the Base Case is 10 EUR.

Is GRF.P stock undervalued or overvalued?

Compared with the current market price of 7.86 EUR, the stock appears Undervalued by 21% .

Back to Top